flâneur

Breaking News: Historical Drop of DR-TB Treatment Cost Below $300 After Third Major Cut in 2025 by Stop TB’s Global Drug Facility | Stop TB Partnership

stoptb.org · 694 words · saved by 1 readers

The Stop TB Partnership’s Global Drug Facility (GDF) has announced a 30% price reduction for bedaquiline produced by Lupin, now available at just $63 per treatment course. This latest decrease brings the lowest cost of the full BPaLM regimen—the most widely recommended treatment for drug-resistant tuberculosis (DR-TB)—below $300 for the first time, now priced at $284 per course. The bedaquiline price cut is projected to generate over $4.5 million in annual savings for GDF clients and high-burden countries that reference GDF prices in their own procurement negotiations. Savings from this price reduction alone could enable the purchase of 71,000 additional bedaquiline courses or 16,000 full BPaLM treatment regimens each year. This announcement follows two earlier price reductions in 2025: Together, these are the third consecutive price reductions over a 6-month period by GDF for key DR-TB medicines, dramatically improving affordability and access. In total, six WHO-recommended DR-TB regi

NEWS ALERT 3 September 2025 | Geneva, Switzerland Life-Saving DR-TB Treatments Even More Affordable Following Newest Bedaquiline Price Decrease The Stop TB Partnership’s Global Drug Facility (GDF) has announced a 30% price reduction for bedaquiline produced by Lupin, now available at just $63 per treatment course . This latest decrease brings the lowest cost of the full BPaLM regimen —the most widely recommended treatment for drug-resistant tuberculosis (DR-TB)— below $300 for the first time , now priced at $284 per course. The bedaquiline price cut is projected to generate over $4.5 million i

saved by

related reading